Objetivo Curative therapies still do not exist for most CNS diseases but gene therapy is a promising new approach. We propose that it will be possible to modify brain function and pathophysiology by targeted delivery of specific curative factors to selected populations of brain cells that are affected by disease. This opens the door for effective treatment regimes, which can be tailored to individual patients needs. However, currently available gene transfer vectors have limitations regarding safety and efficacy, as they do not allow for targeting of specific populations of neurons or glia or regulation of transgene expression. The NEUGENE consortium has been founded by leading European scientists from academia and industry to overcome these limitations. The consortium will develop Adeno-associated virus (AAV) and Lentivirus (LV)- based tools for targeted and regulated gene transfer into different populations of CNS cells. The consortium will provide a selection of vectors that are optimized for different therapeutic approaches, e.g. regulated expression of neurotrophic factors or manipulation of neurotransmitter synthesis in specific neurons. NEUGENE has three major goals:1) targeting gene transfer vectors to specific populations of neurons and glia, by transcriptional regulation and miRNA-mediated de-targeting and by exploiting the cell-specific tropism of novel types of viral vectors, 2) tight control over expression levels of therapeutic genes by using regulated systems based on different principles, and 3) establishing the safety of the novel vector tools. NEUGENE will verify the functional efficacy of the novel CNS gene transfer tools in a well-established animal model of Parkinson's Disease (PD). This disorder affects over 1.000.000 Europeans and is increasing in prevalence with the aging population. Importantly, principles and mechanisms developed and evaluated within the consortium will also be of direct relevance for gene therapy of many other brain disorder. Ámbito científico medical and health sciencesmedical biotechnologygenetic engineeringgene therapynatural sciencesbiological sciencesmicrobiologyvirologymedical and health sciencesbasic medicinephysiologypathophysiologymedical and health sciencesbasic medicineneurologyparkinson Programa(s) FP7-HEALTH - Specific Programme "Cooperation": Health Tema(s) HEALTH-2007-1.4-5 - Gene therapy tools targeting the central nervous system Convocatoria de propuestas FP7-HEALTH-2007-B Consulte otros proyectos de esta convocatoria Régimen de financiación CP-FP - Small or medium-scale focused research project Coordinador UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTS Aportación de la UE € 690 800,00 Dirección Robert-Koch-Strasse 40 37075 Goettingen Alemania Ver en el mapa Región Niedersachsen Braunschweig Göttingen Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Christiane Hennecke (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos Participantes (5) Ordenar alfabéticamente Ordenar por aportación de la UE Ampliar todo Contraer todo MAX IV Laboratory, Lund University Suecia Aportación de la UE € 700 800,00 Dirección Paradisgatan 5c 22100 LUND Ver en el mapa Región Södra Sverige Sydsverige Skåne län Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Eva Nordin (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE Reino Unido Aportación de la UE € 300 000,00 Dirección EGHAM HILL UNIVERSITY OF LONDON TW20 0EX Egham Ver en el mapa Región South East (England) Surrey, East and West Sussex West Surrey Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Jenny Febry (Ms.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES Francia Aportación de la UE € 756 000,00 Dirección RUE LEBLANC 25 75015 PARIS 15 Ver en el mapa Región Ile-de-France Ile-de-France Paris Tipo de actividad Research Organisations Contacto administrativo Olivier Leroy (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE Suiza Aportación de la UE € 452 400,00 Dirección BATIMENT CE 3316 STATION 1 1015 Lausanne Ver en el mapa Región Schweiz/Suisse/Svizzera Région lémanique Vaud Tipo de actividad Higher or Secondary Education Establishments Contacto administrativo Patrick Aebischer (Prof.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos OXFORD BIOMEDICA (UK) LIMITED Reino Unido Aportación de la UE € 100 000,00 Dirección OXFORD SCIENCE PARK MEDAWAR OX4 4GA OXFORD Ver en el mapa Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Contacto administrativo Peter Nolan (Mr.) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Coste total Sin datos